The Combination of Lenalidomide and Dexamethasone With or Without Intensification by High-dose Melphalan in the Treatment of Multiple Myeloma.
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 19 Aug 2015 Planned End Date changed from 1 Apr 2015 to 1 Jan 2020 as reported by ClinicalTrials.gov
- 19 Aug 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Dec 2019 as reported by ClinicalTrials.gov
- 10 Dec 2012 Interim results from safety analysis of 100 patients presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.